CA2241880A1 - Inhalation device - Google Patents
Inhalation device Download PDFInfo
- Publication number
- CA2241880A1 CA2241880A1 CA002241880A CA2241880A CA2241880A1 CA 2241880 A1 CA2241880 A1 CA 2241880A1 CA 002241880 A CA002241880 A CA 002241880A CA 2241880 A CA2241880 A CA 2241880A CA 2241880 A1 CA2241880 A1 CA 2241880A1
- Authority
- CA
- Canada
- Prior art keywords
- conduit
- plates
- medicament
- outlet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0048—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged in a plane, e.g. on diskettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/04—Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, or spherical or like small articles, e.g. tablets or pills
- B65D83/0445—Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, or spherical or like small articles, e.g. tablets or pills all the articles being stored in individual compartments
- B65D83/0454—Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, or spherical or like small articles, e.g. tablets or pills all the articles being stored in individual compartments the whole forming a circular container with rotating parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2583/00—Containers or packages with special means for dispensing contents
- B65D2583/04—For dispensing annular, disc-shaped or spherical or like small articles or tablets
- B65D2583/0404—Indications, e.g. directions for use
- B65D2583/0409—Indications, e.g. directions for use of dates or follow-numbers
Abstract
A powder inhalation device comprising a housing containing a pharmacologically active compound, a conduit (8) with an outlet extending into the housing through which a user can inhale to create an airflow through the conduit, a dosing unit (6, 7) for delivering a dose of the compound to the conduit and baffles (9) arranged within the said conduit to aid disintegration of powder agglomerates entrained in said airflow. The baffles (9) comprise a plurality of staggered plates extending into the conduit from opposite sides of the conduit at an angle of less than 90~ to the sides of the conduit and are inclined towards the outlet to create a plurality of constrictions within the conduit and a plurality of changes in the direction of the said airflow through the conduit.
Description
INHALATION DEVICE
This invention relates to an inhalation device by means of which metered doses of medicament in the form of a powder can be dispensed to a user.
Inhalation devices are known to be used for local administration of drugs to the respiratory tract and lungs of patients. One such device for use with blister packs in which the medicament is held in powder form in the blisters thereof is known as the DISKHALER inhalation device and is described in UK Patent No.
2178965. In use, a fresh blister is indexed to bring it into registration with a use station and then punctured with a puncturing member in two distinct actions to enable the medicament to be inhaled thererlo"l.
Another inhalation device described in UK Patent No. 2242134 is for use with 15 peelable medicament packs defining containers for holding the medicament and includes a means for peeling the medicament pack apart to open each container in turn as they are brought into registration with a use station. This device is somewhat complex and contains many components.
20 Medicament for administration by inhalation should be of a controlled particle size in order to achie~e maximum penetration in to the tungs, preferably in the range of 1 to 10 micrometers in diameter and more preferably 1 to 5 micrometers. Unfortunately, powders in this particle size range, hereinafter referred to as fine powders, for example micronised powders, usually have very poor flow characteristics. due to the cohesive forces ~etween the individual .particles which make them readily agglomerate together to form bridges which are not readily broken apart to become free flowing. These characteristics 5 create handling and metering difficulties which adversely affect the accurate dispensing of doses of the powder. However, co-pending PCT Patent Application No. EP96.03274 describes how, by careful sizing of fine agglomerated powder, it is possible to make use of the cohesive forces between the particles to create agglomerates of powder which are free flowing. These 10 agglomerates of powder can be easily handled and may be used to conveniently fill devices.
However, for efficient delivery to the lungs, the powder agglomerates must be broken down before they leave such a device, back into a controlled size.
It has been found that it is possible to break up powder agglomerates in the airflow as a user inhales by incorporating a series of baffles in the mouthpiece of a powder inhalation device. EP 0 237 507 describes baffles which comprise helical channel portions which give the airflow a rotating, helical pattern of 20 motion.
However, one disadvantage associated with the baffles described in EP 0 237 507 in that the baffles comprise a number of components rendering the device manufacturing process relatively complicated and expensive.
GB 2191718 relates to aerosol devices for dispensing nicotine. The nicotine dispensing device has an impaction means designed to separate the spray allowing the smaller particles and vapour phase to flow around the baffle while the larger particles are removed.
PCTIEP~3/00582 also describes a device co,nprising baffles which are acting as sep~, ator~, but if the aerosol contains larger particles in the form of relativeiy loose agglo~,er~tes, these agglomerates are reduced in size if their velocity ofimpact against the baffles is sufficiently high.
One disadvantage of the two sets of baffles described in GB 2191718 and PCT/EP93/00582 is the high deposition of powder which can occur due to the baffles extending from the walls of the device at 90~ to the direction of airflow. This may result in deposition of the larger agglomerates of powder occurring, which agglomerates could become loose in subsequent inhalations and result in variations in dosage.
W O 97nso86 PCT/GB96/03141 It is an object of the invention to provide a device of the type just described which is simple for a user to operate and which is not unduly complex in its assembly. It is a further object to provide a device which may be filled with powder agglomerates but will deliver powder in a form suitable for administration by inhalation.
According to the present invention there is provided an inhalation device comp,ising a housing, an outlet through which a user can inhale, a medicament holder defining at least one pocket for containing a single dose of medicament in the form of a powder, a closure member having at least one closure pad 10 resiliently urged into contact with the medica",ent holder to close the ssid at least one pocket, means for moving the pocket into registlalion with the outlet and means for lifting the closure pad away from the medicament holder to open the pocket when the pocket is brought into registration with the outlet.
15 Such a device is simple to operate requiring only one distinct action to enable the medicament to be inhaled therefrom. The device may also comprise relatively few components.
Accordin~ to the invention there is also provided a powder inhalation device 20 comprising a housing containing a pharmacologically active compound or medicament, a conduit with an outlet extending into the housing through which a user can inhale to create an airflow through the conduit, a dosing unit for CA 0224l880 l998-06-30 delivering a dose of the compound to the conduit and baffles arranged within the said conduit to aid disintegration of powder agglomerates entrained in said airflow, characterised in that the baffles comprise a plurality of staggered plates extending into the conduit from opposite sides of the conduit at an angle of less 5 than 90~ to the sides of the conduit and are inclined towards the outlet to create a plurality of constrictions within the conduit and a plurality of changes in the direction of the said airflow through the conduit.
By use of this arrangement it is possible to provide baffles which are simple to 10 manufacture and proYide low deposition of powder, and yet which give good results in breaking agglomerates down into discrete constituent particles to create a powder of respirable size.
Preferably the device contains at least 2 plates and more preferably 4 plates.
Preferably the said plates are inclined at an angle less than 70~ to the longitudinal axis of the conduit in the direction of airflow and more preferably the said plates are inclined at an angle in the range of 15~ to 50~.
20 Suitably the penultimate baffle is shaped so that at some point along the plate it divides into at least 2 faces, the first face of which continues to extend into the conduit and a second face of which extends towards the outlet substantially parallel to the longitudinal axis of the conduit. This enables the airflow to exit parallel to the said axis delivering the powder directly to the user's respiratory tract and not into the cheek cavity of the user.
An embodiment of the invention is further described below with reference to the accompanying drawings in which:
Figure 1 is a perspective view of an assembled device according to the invention;
Figure 2 is an exploded perspective view of the device of Figure 1 showing the 10 main body components and primary pack;
Figure 3 is an exploded perspective view of the device showing each component in disassembled form;
Figure 4 is a plan view partly in section showing air flow through a pre~"~d embodiment of the invention;
15 Figure 5 is a perspective view showing airflow through the device shown in Figure 4; and Figure 6 is a cut away view showing the pocket closure pad held in the raised position 20 The device shown in Figures 1 to 3 comprises a body 1 formed of a body base 2 and a body top 3, both of which may be moulded from a plastics material such as acryl-butyl styrene (ABS). Body top 3 is formed with window 4 the purpose of which is described below. The body 1 defines a main housing section adapted to contain a primary pack comprising a dose ring 6 and closure means in the W O 97~5086 PCT/GB96/03141 form of a spider 7, and a mouthpiece section 8 forming an outlet through which a user can inhale extending radially from the main housing section. As seen in Figure 2, the mouthpiece section 8 of body base 2 is formed with a plurality of baffles 9 which are explained below.
A medicament holder in the form of a disk or dose ring 6 comprises an upper surface formed with a plurality of cavities or pockets 10 for containing inhalable powdered medicament to be dispensed from the device. Each pocket 10 is surrounded by a raised lip (not shown). The dose ring shown is provided with 10 ten pockets 1~ which might be suitable for containing ten days' supply of medicament or sufficient medicament for a single course of treatment. It will be understood that the dose ring might haYe more or fewer pockets depending on the medicament to be contained. Suitable powdered medicaments are, for example, for the treatment of asthma, and include salbutamol, beclomethasone, ~5 salmeterol, fluticasone, formoterol, terbutaline, budesonide and flunisolide, and physiologically acceptable salts, solvates and esters or any combination thereof. Preferred medicaments are salbutamol, salbutamol sulphate, salmeterol, salmeterol xinafoate, fluticasone propionate, beclomethasone dipropionate or solvates thereof and terbutaline sulphate. Other suitable 20 powdered medicaments include antiviral medicaments, for example zanamivir (4-guanidino-Neu-5-Ac-2-en) It will be appreciated by those skilled in the art that the powder medicament, may, if desired, be a combination of two or more W O 97~5086 PCT/GB96/03141 active ingredients. A dose may be constituted from the contents of one or more cavities and the size of each cavity will depend on the dose to be delivered. It is to be understood that the medicament powder may consist purely of one or more active ingredients, or there may additionally be a carrier, for example 5 lactose powder.
The dose ring 6 may be adapted for filling with agglomerated powder in accordance with the method and apparatus described in co-pending PCT Patent Application No. ~P96.03274 The Jose ring 6 has a stepped peripheral edge the purpose of whioh is explained below, and a splined hole in the centre for engage",enl with the spider 7. The dose ring may also be moulded from a plastics material such as ABS.
The spider 7 comprises a central ring shaped section 11 from which extend a plurality of resilient radial arms 12, the number of which corresponds to the number of pockets 10 in the dose ring 6. Each radial arm 12 terminates in a pocket closure pad 13. A plurality of short resilient hooked tabs 14 extend 20 axially from the central ring shaped section 11 and are adapted to form a snap-fit with the dose ring 6 by engaging with the splined hole in the centre of the dose ring 6. The spider 7 may be moulded from a plastics material such as W O 97/25086 PC~rlG B96/03141 polycarbonate or any other engineering plastics which has the required resiliency characteristics. When the spider 7 is assembled to the dose ring 6 to .form the dosing unit or primary pack the hooked tabs 14 tightly engage the splined hole in the dose ring 6 and each pocket closure pad 13 is resiliently 5 urged into contact with a respective raised lip on the upper surface of the dose ring 6 by means of the resilient radial arms 12 in such a position as to cover and seal a respective pocket 10 to prevent loss of medicament from and ingression of moisture into the pocket. The poc~cet closure pads may be moulded with a smooth flat contact face which seals directly on the upper surface of the dose 10 ring 6 or raised lip 28 (Figure 6) or alternatively may ~e provided with a soft sealing material such as a thelr"oplaslic elaslo",er eg SANTOPRENF (Bayer~
formed on the contact face to improve the sealing characteristics. To manufacture the spider 7 with a differenl sealing material on the pocket closure pad the spider may be moulaed with a channel 15 formed in the upper face of 15 the central ring shaped section 11 and in each radial arm 12 and a small hole (not shown) leading from the end of the channel 15 in each arm 12 through to the underside of the pocket closure pads 13. The sealing material in a molten state may then be made to flow round channel 15 and through the holes to the underside of each of the pocket closure pads 13 to form an integral cushion seal 20 on each pad upon cooling.
W O 97n5086 PCT/GB96/03141 The upper faces of the pocket closure pads 13 may have a number 17 or other indicating means moulded or printed thereon to give an indication as to how many doses of medicament remain in the device as is explained further below.
5 An edge of each pocket closure pad 13 is formed with a tab 16 adapted for engagement with a ramp 20 (Figures 4 and 5) integrally formed with body top 3 to effect opening of the pocket as explained below.
The primary pack fits into the main housing section of the body 1 as shown in Figures 2 and 3 such that axle 21 of body base 2 is located wit~iin the hole in the primary pack and the stepped peripheral edge of the dose ring protrudes through two cut away s~ctions on opposite sides of the main housing section.
Pawl 24 on body base 2 en~ages with teeth (not shown) on the underside of dose ring 6 to create a ratchet mechanism which only allows movement of the 15 dose ring in one direction.
Pockets 10 may be filled with agglomerated powder as described in PCT patent application no. PCT EP96.03274. When so filled, for inhalation therapy it is essential that the largest possible quantity of primary particles inhaled is in the 20 respirable range, that is smaller than 5 microns. In order to aid break-up of any powder agglornerates entrained in the air flow a series of baffles 9 are located in the mouthpiece section 8. As will be explained later, the position of the baffles W O 97nso86 PCT/GB96103141 are important. The baffles can be formed in a single moulding with the body, so affording consistent, controlled and repeatable tolerance. It will be understood that the number and exact dimensions of baffles present will depend on the powder being used and the strength of the forces holding the agglomerates 5 together. For example, it has been found that four baffles achieved the required break up of powder agglomerates of zanamivir. It would be entirely straight forward for a skilled person to experiment with the baffle dimensions to obtain desired flow resistance for a particular powder.
10 Figures 4 and 5 show a prefe"ed arrangement of baffles 9 comprisin~ of a plurality of staggered flat plates which extend into the conduit at angles of 30~ to the longitudinal axis of the conduit from opposite sides of the housing. Most of the bafnes extend beyond the longitudinal axis of the conduit with the final baffle 25 in the direction of airflow stopping short of the axis. The penultimate baffle 15 26 in the direction of the airflow has an extended flat face 27 running parallel to the longitudinal axis of the conduit and extending towards the outlet. This enables the airflow to exit parallel to the said axis delivering the powder directly to the user's respiratory tract and not into the cheek cavity of the user.
20 A mouthpiece cover 22 is adapted to fit over the mouthpiece section 8 when the deYice is not in use to prevent contamination of the mouthpiece by dust. The mouthpiece cover has two pins 30 adapted to pass through two slots 23 into the W O 97125086 PCTtGB96103141 main housing section of body 1 either side of the mouthpiece section 8 to engage the stepped peripheral edge of the dose ring and so lock the primary pack to prevent accidental movement thereof when the device is not in use.
To operate the device the user first removes mouthpiece cover 22 thereby 5 unlocking the primary pack. The user then indexes a pocket to bring it into registration with the mouthpiece by holding the stepped peripheral edge of the dose ring where it protrudes through the cut away sections of the main housing section and rotating the dose ring 6 relative to the body 1. The ratchet mechanism described above allows rotation of the primary pack in one clirectiotl 10 only. As the primary pack rotates, tab 16 of the next pocket closure pad 13 engages ramp 20 and pocket closure pad 13 is lifted away from the upper surface of the dose ring 6 as the tab rides over the ramp. As the pocket comes into registration with the mouthpiece, the raised lip 28 (Figure 6) surrounding the pocket 10 engages with the sides of the exit channel 29 creating an 15 increased resistance to motion of the dose ring, so giving a clear indication to the user that the dose ring is in position ready for delivery of medicament.
As the raised lip 28 surrounding the pocket 10 engages with the exit channel 29 the pocket closure pad 13 is in a raised position clear of the upper surface of 20 the dose ring 6 as shown in Figure 6. In this position, pocket closure pad 13 is situated directly beneath window 4 in body top 3 such that the number 17 or other dose indicating means moulded or printed on the upper face of the pocket W O 97/2S086 PCT/GB96/0314~
closure pad 13 is clearly visible through window 4. This allows the user to see how many doses remain in the device.
The dose of medicament contained in pocket 10 is now ready for delivery. The 5 user inhales through mouthpiece 8. Air is drawn into the device via slots 23 and directed over the open pocket 10 as seen in Figures 4 and 5. As the air flows over pocket 10, medicament powder in the pocket is entrained in the tur~ulent air flow, drawn through the mouthpiece section 8 and inhaled by the user.
10 As seen in Figure 5, baffles 9 are arranged to disrupt the sllloolll flow of air through the mouthpiece to create additional turbulence, cause the air flow to change direction several times to cause any agglomerates of powder to collide with the baffles, walls and other agglomerates, and constr.ct the air flow to increase the flow velocity. The air circulation produces eddy currents in the 15 back waters of the baffles creating further collisions to aid in the break up of the powder agglomerates. This is shown by the arrows representing air flow in Figure 5. All of these effects promote the disintegration of powder agglomerates entrained in the air flow to render the powder in a form suitable for inhalation therapy. The extended flat face 27 running parallel to the longitudinal axis of the 20 conduit attached to the penultimate baffle in the direction of airflow enables the airflow to exit parallel to the said axis delivering the powder directly to the users respiratory tract and not into the cheek cavity of the user.
After inhalation the user replaces mouthpiece cover 22 to protect and lock the deYice until the next dose is required to be delivered.
5 It will be understood that the present disclosure is for the purpose of illustration only and the invention extends to modifications, variations and improvements thereto.
This invention relates to an inhalation device by means of which metered doses of medicament in the form of a powder can be dispensed to a user.
Inhalation devices are known to be used for local administration of drugs to the respiratory tract and lungs of patients. One such device for use with blister packs in which the medicament is held in powder form in the blisters thereof is known as the DISKHALER inhalation device and is described in UK Patent No.
2178965. In use, a fresh blister is indexed to bring it into registration with a use station and then punctured with a puncturing member in two distinct actions to enable the medicament to be inhaled thererlo"l.
Another inhalation device described in UK Patent No. 2242134 is for use with 15 peelable medicament packs defining containers for holding the medicament and includes a means for peeling the medicament pack apart to open each container in turn as they are brought into registration with a use station. This device is somewhat complex and contains many components.
20 Medicament for administration by inhalation should be of a controlled particle size in order to achie~e maximum penetration in to the tungs, preferably in the range of 1 to 10 micrometers in diameter and more preferably 1 to 5 micrometers. Unfortunately, powders in this particle size range, hereinafter referred to as fine powders, for example micronised powders, usually have very poor flow characteristics. due to the cohesive forces ~etween the individual .particles which make them readily agglomerate together to form bridges which are not readily broken apart to become free flowing. These characteristics 5 create handling and metering difficulties which adversely affect the accurate dispensing of doses of the powder. However, co-pending PCT Patent Application No. EP96.03274 describes how, by careful sizing of fine agglomerated powder, it is possible to make use of the cohesive forces between the particles to create agglomerates of powder which are free flowing. These 10 agglomerates of powder can be easily handled and may be used to conveniently fill devices.
However, for efficient delivery to the lungs, the powder agglomerates must be broken down before they leave such a device, back into a controlled size.
It has been found that it is possible to break up powder agglomerates in the airflow as a user inhales by incorporating a series of baffles in the mouthpiece of a powder inhalation device. EP 0 237 507 describes baffles which comprise helical channel portions which give the airflow a rotating, helical pattern of 20 motion.
However, one disadvantage associated with the baffles described in EP 0 237 507 in that the baffles comprise a number of components rendering the device manufacturing process relatively complicated and expensive.
GB 2191718 relates to aerosol devices for dispensing nicotine. The nicotine dispensing device has an impaction means designed to separate the spray allowing the smaller particles and vapour phase to flow around the baffle while the larger particles are removed.
PCTIEP~3/00582 also describes a device co,nprising baffles which are acting as sep~, ator~, but if the aerosol contains larger particles in the form of relativeiy loose agglo~,er~tes, these agglomerates are reduced in size if their velocity ofimpact against the baffles is sufficiently high.
One disadvantage of the two sets of baffles described in GB 2191718 and PCT/EP93/00582 is the high deposition of powder which can occur due to the baffles extending from the walls of the device at 90~ to the direction of airflow. This may result in deposition of the larger agglomerates of powder occurring, which agglomerates could become loose in subsequent inhalations and result in variations in dosage.
W O 97nso86 PCT/GB96/03141 It is an object of the invention to provide a device of the type just described which is simple for a user to operate and which is not unduly complex in its assembly. It is a further object to provide a device which may be filled with powder agglomerates but will deliver powder in a form suitable for administration by inhalation.
According to the present invention there is provided an inhalation device comp,ising a housing, an outlet through which a user can inhale, a medicament holder defining at least one pocket for containing a single dose of medicament in the form of a powder, a closure member having at least one closure pad 10 resiliently urged into contact with the medica",ent holder to close the ssid at least one pocket, means for moving the pocket into registlalion with the outlet and means for lifting the closure pad away from the medicament holder to open the pocket when the pocket is brought into registration with the outlet.
15 Such a device is simple to operate requiring only one distinct action to enable the medicament to be inhaled therefrom. The device may also comprise relatively few components.
Accordin~ to the invention there is also provided a powder inhalation device 20 comprising a housing containing a pharmacologically active compound or medicament, a conduit with an outlet extending into the housing through which a user can inhale to create an airflow through the conduit, a dosing unit for CA 0224l880 l998-06-30 delivering a dose of the compound to the conduit and baffles arranged within the said conduit to aid disintegration of powder agglomerates entrained in said airflow, characterised in that the baffles comprise a plurality of staggered plates extending into the conduit from opposite sides of the conduit at an angle of less 5 than 90~ to the sides of the conduit and are inclined towards the outlet to create a plurality of constrictions within the conduit and a plurality of changes in the direction of the said airflow through the conduit.
By use of this arrangement it is possible to provide baffles which are simple to 10 manufacture and proYide low deposition of powder, and yet which give good results in breaking agglomerates down into discrete constituent particles to create a powder of respirable size.
Preferably the device contains at least 2 plates and more preferably 4 plates.
Preferably the said plates are inclined at an angle less than 70~ to the longitudinal axis of the conduit in the direction of airflow and more preferably the said plates are inclined at an angle in the range of 15~ to 50~.
20 Suitably the penultimate baffle is shaped so that at some point along the plate it divides into at least 2 faces, the first face of which continues to extend into the conduit and a second face of which extends towards the outlet substantially parallel to the longitudinal axis of the conduit. This enables the airflow to exit parallel to the said axis delivering the powder directly to the user's respiratory tract and not into the cheek cavity of the user.
An embodiment of the invention is further described below with reference to the accompanying drawings in which:
Figure 1 is a perspective view of an assembled device according to the invention;
Figure 2 is an exploded perspective view of the device of Figure 1 showing the 10 main body components and primary pack;
Figure 3 is an exploded perspective view of the device showing each component in disassembled form;
Figure 4 is a plan view partly in section showing air flow through a pre~"~d embodiment of the invention;
15 Figure 5 is a perspective view showing airflow through the device shown in Figure 4; and Figure 6 is a cut away view showing the pocket closure pad held in the raised position 20 The device shown in Figures 1 to 3 comprises a body 1 formed of a body base 2 and a body top 3, both of which may be moulded from a plastics material such as acryl-butyl styrene (ABS). Body top 3 is formed with window 4 the purpose of which is described below. The body 1 defines a main housing section adapted to contain a primary pack comprising a dose ring 6 and closure means in the W O 97~5086 PCT/GB96/03141 form of a spider 7, and a mouthpiece section 8 forming an outlet through which a user can inhale extending radially from the main housing section. As seen in Figure 2, the mouthpiece section 8 of body base 2 is formed with a plurality of baffles 9 which are explained below.
A medicament holder in the form of a disk or dose ring 6 comprises an upper surface formed with a plurality of cavities or pockets 10 for containing inhalable powdered medicament to be dispensed from the device. Each pocket 10 is surrounded by a raised lip (not shown). The dose ring shown is provided with 10 ten pockets 1~ which might be suitable for containing ten days' supply of medicament or sufficient medicament for a single course of treatment. It will be understood that the dose ring might haYe more or fewer pockets depending on the medicament to be contained. Suitable powdered medicaments are, for example, for the treatment of asthma, and include salbutamol, beclomethasone, ~5 salmeterol, fluticasone, formoterol, terbutaline, budesonide and flunisolide, and physiologically acceptable salts, solvates and esters or any combination thereof. Preferred medicaments are salbutamol, salbutamol sulphate, salmeterol, salmeterol xinafoate, fluticasone propionate, beclomethasone dipropionate or solvates thereof and terbutaline sulphate. Other suitable 20 powdered medicaments include antiviral medicaments, for example zanamivir (4-guanidino-Neu-5-Ac-2-en) It will be appreciated by those skilled in the art that the powder medicament, may, if desired, be a combination of two or more W O 97~5086 PCT/GB96/03141 active ingredients. A dose may be constituted from the contents of one or more cavities and the size of each cavity will depend on the dose to be delivered. It is to be understood that the medicament powder may consist purely of one or more active ingredients, or there may additionally be a carrier, for example 5 lactose powder.
The dose ring 6 may be adapted for filling with agglomerated powder in accordance with the method and apparatus described in co-pending PCT Patent Application No. ~P96.03274 The Jose ring 6 has a stepped peripheral edge the purpose of whioh is explained below, and a splined hole in the centre for engage",enl with the spider 7. The dose ring may also be moulded from a plastics material such as ABS.
The spider 7 comprises a central ring shaped section 11 from which extend a plurality of resilient radial arms 12, the number of which corresponds to the number of pockets 10 in the dose ring 6. Each radial arm 12 terminates in a pocket closure pad 13. A plurality of short resilient hooked tabs 14 extend 20 axially from the central ring shaped section 11 and are adapted to form a snap-fit with the dose ring 6 by engaging with the splined hole in the centre of the dose ring 6. The spider 7 may be moulded from a plastics material such as W O 97/25086 PC~rlG B96/03141 polycarbonate or any other engineering plastics which has the required resiliency characteristics. When the spider 7 is assembled to the dose ring 6 to .form the dosing unit or primary pack the hooked tabs 14 tightly engage the splined hole in the dose ring 6 and each pocket closure pad 13 is resiliently 5 urged into contact with a respective raised lip on the upper surface of the dose ring 6 by means of the resilient radial arms 12 in such a position as to cover and seal a respective pocket 10 to prevent loss of medicament from and ingression of moisture into the pocket. The poc~cet closure pads may be moulded with a smooth flat contact face which seals directly on the upper surface of the dose 10 ring 6 or raised lip 28 (Figure 6) or alternatively may ~e provided with a soft sealing material such as a thelr"oplaslic elaslo",er eg SANTOPRENF (Bayer~
formed on the contact face to improve the sealing characteristics. To manufacture the spider 7 with a differenl sealing material on the pocket closure pad the spider may be moulaed with a channel 15 formed in the upper face of 15 the central ring shaped section 11 and in each radial arm 12 and a small hole (not shown) leading from the end of the channel 15 in each arm 12 through to the underside of the pocket closure pads 13. The sealing material in a molten state may then be made to flow round channel 15 and through the holes to the underside of each of the pocket closure pads 13 to form an integral cushion seal 20 on each pad upon cooling.
W O 97n5086 PCT/GB96/03141 The upper faces of the pocket closure pads 13 may have a number 17 or other indicating means moulded or printed thereon to give an indication as to how many doses of medicament remain in the device as is explained further below.
5 An edge of each pocket closure pad 13 is formed with a tab 16 adapted for engagement with a ramp 20 (Figures 4 and 5) integrally formed with body top 3 to effect opening of the pocket as explained below.
The primary pack fits into the main housing section of the body 1 as shown in Figures 2 and 3 such that axle 21 of body base 2 is located wit~iin the hole in the primary pack and the stepped peripheral edge of the dose ring protrudes through two cut away s~ctions on opposite sides of the main housing section.
Pawl 24 on body base 2 en~ages with teeth (not shown) on the underside of dose ring 6 to create a ratchet mechanism which only allows movement of the 15 dose ring in one direction.
Pockets 10 may be filled with agglomerated powder as described in PCT patent application no. PCT EP96.03274. When so filled, for inhalation therapy it is essential that the largest possible quantity of primary particles inhaled is in the 20 respirable range, that is smaller than 5 microns. In order to aid break-up of any powder agglornerates entrained in the air flow a series of baffles 9 are located in the mouthpiece section 8. As will be explained later, the position of the baffles W O 97nso86 PCT/GB96103141 are important. The baffles can be formed in a single moulding with the body, so affording consistent, controlled and repeatable tolerance. It will be understood that the number and exact dimensions of baffles present will depend on the powder being used and the strength of the forces holding the agglomerates 5 together. For example, it has been found that four baffles achieved the required break up of powder agglomerates of zanamivir. It would be entirely straight forward for a skilled person to experiment with the baffle dimensions to obtain desired flow resistance for a particular powder.
10 Figures 4 and 5 show a prefe"ed arrangement of baffles 9 comprisin~ of a plurality of staggered flat plates which extend into the conduit at angles of 30~ to the longitudinal axis of the conduit from opposite sides of the housing. Most of the bafnes extend beyond the longitudinal axis of the conduit with the final baffle 25 in the direction of airflow stopping short of the axis. The penultimate baffle 15 26 in the direction of the airflow has an extended flat face 27 running parallel to the longitudinal axis of the conduit and extending towards the outlet. This enables the airflow to exit parallel to the said axis delivering the powder directly to the user's respiratory tract and not into the cheek cavity of the user.
20 A mouthpiece cover 22 is adapted to fit over the mouthpiece section 8 when the deYice is not in use to prevent contamination of the mouthpiece by dust. The mouthpiece cover has two pins 30 adapted to pass through two slots 23 into the W O 97125086 PCTtGB96103141 main housing section of body 1 either side of the mouthpiece section 8 to engage the stepped peripheral edge of the dose ring and so lock the primary pack to prevent accidental movement thereof when the device is not in use.
To operate the device the user first removes mouthpiece cover 22 thereby 5 unlocking the primary pack. The user then indexes a pocket to bring it into registration with the mouthpiece by holding the stepped peripheral edge of the dose ring where it protrudes through the cut away sections of the main housing section and rotating the dose ring 6 relative to the body 1. The ratchet mechanism described above allows rotation of the primary pack in one clirectiotl 10 only. As the primary pack rotates, tab 16 of the next pocket closure pad 13 engages ramp 20 and pocket closure pad 13 is lifted away from the upper surface of the dose ring 6 as the tab rides over the ramp. As the pocket comes into registration with the mouthpiece, the raised lip 28 (Figure 6) surrounding the pocket 10 engages with the sides of the exit channel 29 creating an 15 increased resistance to motion of the dose ring, so giving a clear indication to the user that the dose ring is in position ready for delivery of medicament.
As the raised lip 28 surrounding the pocket 10 engages with the exit channel 29 the pocket closure pad 13 is in a raised position clear of the upper surface of 20 the dose ring 6 as shown in Figure 6. In this position, pocket closure pad 13 is situated directly beneath window 4 in body top 3 such that the number 17 or other dose indicating means moulded or printed on the upper face of the pocket W O 97/2S086 PCT/GB96/0314~
closure pad 13 is clearly visible through window 4. This allows the user to see how many doses remain in the device.
The dose of medicament contained in pocket 10 is now ready for delivery. The 5 user inhales through mouthpiece 8. Air is drawn into the device via slots 23 and directed over the open pocket 10 as seen in Figures 4 and 5. As the air flows over pocket 10, medicament powder in the pocket is entrained in the tur~ulent air flow, drawn through the mouthpiece section 8 and inhaled by the user.
10 As seen in Figure 5, baffles 9 are arranged to disrupt the sllloolll flow of air through the mouthpiece to create additional turbulence, cause the air flow to change direction several times to cause any agglomerates of powder to collide with the baffles, walls and other agglomerates, and constr.ct the air flow to increase the flow velocity. The air circulation produces eddy currents in the 15 back waters of the baffles creating further collisions to aid in the break up of the powder agglomerates. This is shown by the arrows representing air flow in Figure 5. All of these effects promote the disintegration of powder agglomerates entrained in the air flow to render the powder in a form suitable for inhalation therapy. The extended flat face 27 running parallel to the longitudinal axis of the 20 conduit attached to the penultimate baffle in the direction of airflow enables the airflow to exit parallel to the said axis delivering the powder directly to the users respiratory tract and not into the cheek cavity of the user.
After inhalation the user replaces mouthpiece cover 22 to protect and lock the deYice until the next dose is required to be delivered.
5 It will be understood that the present disclosure is for the purpose of illustration only and the invention extends to modifications, variations and improvements thereto.
Claims (27)
1 An inhalation device comprising a housing, an outlet through which a user can inhale, a medicament holder defining at least one pocket for containing a single dose of medicament in the form of a powder, a closure member having at least one closure pad resiliently urged into contact with the medicament holder to close the said at least one pocket, means for moving the pocket into registration with the outlet and means for lifting the closure pad away from the medicament holder to open the pocket when the pocket is brought into registration with the outlet, wherein the rotation of the medicament holder causes the closure pad to be lifted away from the medicament holder.
2. A device as claimed in claim 1, wherein said medicament holder comprises a disk which is rotatably mounted in the device with the at least one pocket arranged on one face of the said disk.
3. A device as claimed in claims 1 or 2, wherein each said closure pad is resiliently urged into contact with the medicament holder by means of a respective resilient arm.
4. A device as claimed in claim 3 comprising a plurality of closure pads, wherein the closure member comprises a plurality of resilient arms connected together in the form of a spider.
5. A device as claimed in claim 4, wherein said spider is made from polycarbonate.
6. A device as claimed in any one of the preceding claims, wherein said closure pad comprises a thermoplastic elastomer.
7. A device as claimed in any of claims 2 to 6, wherein the said disk protrudes from the body of the device to provide means for moving the at least one pocket into registration with the outlet.
8. A device as claimed in claim 7, wherein the said disk is provided with grips at its periphery.
9. A device as claimed in any one of claims 7 or 8, further comprising a ratchet mechanism to allow movement of the disk in only one direction
10. A device as claimed in any one of the preceding claims, wherein the pocket closure pad is lifted away from the surface of the said disk by engagement with a ramp.
11. A device as claimed in any one of the preceding claims, further comprising a removable mouthpiece cover which, when in place, engages with the medicament holder to prevent movement thereof.
12. A device as claimed in any one of the preceding claims, wherein the outlet comprises a conduit in which are arranged a plurality of staggered plates extending into the conduit from opposite sides of the conduit at an angle of less than 90° to the sides of the conduit and which plates are inclined towards the outlet to create a plurality of constrictions within the conduit and a plurality of changes in the direction of the airflow through the conduit.
13. A device as claimed in claim 12 comprising at least 2 plates.
14. A device as claimed in claim 13 comprising 4 plates.
15. A device as claimed in any of claims 12 to 14, wherein the said plates are inclined at an angle less than 70° to the longitudinal axis of the conduit in the direction of airflow.
16 A device as claimed in claim 15, wherein the said plates are inclined at an angle in the range of 15° to 50°.
17. A device as claimed in claim 16, wherein the said plates are inclined at an angle of 30°.
18. A device as claimed in any of claims 12 to 17, wherein the penultimate baffle is shaped so that at some point along the plate it divides into at least 2 faces, the first face of which continues to extend into the conduit and a second face of which extends towards the outlet substantially parallel to the longitudinal axis of the conduit.
19. A device as claimed in any preceding claim, wherein the said pockets are filled with medicament.
20. A powder inhalation device comprising a housing containing a medicament, a conduit with an outlet extending into the housing through which a user can inhale to create an airflow through the conduit, a dosing unit for delivering a dose of the compound to the conduit and baffles arranged within the said conduit to aid disintegration of powder agglomerates entrained in said airflow, wherein the baffles comprise a plurality of staggered plates extending into the conduit from opposite sides of the conduit at an angle of less than 90° to the sides of the conduit and are inclined towards the outlet to create a plurality of constrictions within the conduit and a plurality of changes in the direction of the said airflow through the conduit.
21. A device as claimed in claim 20, comprising at least 2 plates.
22. A device as claimed in claim 21, comprising 4 plates.
23. A device as claimed in any one of claims 20 to 22 wherein the said plates are inclined at an angle less than 70° to the longitudinal axis of the conduit in the direction of airflow.
24. A device as claimed in claim 23, wherein the said plates are inclined at an angle in the range of 15° to 50°.
25. A device as claimed in claim 24 wherein the said plates are inclined at an angle of 30°.
26. A device as claimed in any one of claims 20 to 25, wherein the penultimate baffle is shaped so that at some point along the plate it divides into at least 2 faces, the first face at which continues to extend into the conduit and a second face of which extends towards the outlet substantially parallel to the longitudinal axis of the conduit.
27. A device as claimed in any preceding claim wherein the medicament is zanamivir.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9600044.3 | 1996-01-03 | ||
GBGB9600044.3A GB9600044D0 (en) | 1996-01-03 | 1996-01-03 | Inhalatiion device |
GB9625134.3 | 1996-12-03 | ||
GBGB9625134.3A GB9625134D0 (en) | 1996-12-03 | 1996-12-03 | Powder inhalation device |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2241880A1 true CA2241880A1 (en) | 1997-07-17 |
Family
ID=26308412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002241880A Abandoned CA2241880A1 (en) | 1996-01-03 | 1996-12-19 | Inhalation device |
Country Status (22)
Country | Link |
---|---|
US (1) | US6065472A (en) |
EP (2) | EP0938907B1 (en) |
JP (1) | JP2000503565A (en) |
KR (1) | KR19990077014A (en) |
CN (1) | CN1213974A (en) |
AP (1) | AP9801285A0 (en) |
AT (2) | ATE209053T1 (en) |
AU (1) | AU725348B2 (en) |
BR (1) | BR9612410A (en) |
CA (1) | CA2241880A1 (en) |
CZ (1) | CZ212598A3 (en) |
DE (2) | DE69618624T2 (en) |
EA (2) | EA001016B1 (en) |
ES (2) | ES2167987T3 (en) |
IL (1) | IL125183A0 (en) |
IS (1) | IS4787A (en) |
MX (1) | MX9805409A (en) |
NO (1) | NO983069L (en) |
NZ (1) | NZ324374A (en) |
PL (1) | PL327616A1 (en) |
TR (1) | TR199801265T2 (en) |
WO (1) | WO1997025086A2 (en) |
Families Citing this family (210)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2216418T3 (en) | 1995-12-07 | 2004-10-16 | Jago Research Ag | NOZZLE FOR AN INHALER FOR THE ADMINISTRATION OF VARIOUS DOSE OF A DRY PHARMACOLOGICAL POWDER. |
US7131441B1 (en) | 1995-12-07 | 2006-11-07 | Skyepharma Ag | Inhaler for multiple dosed administration of a pharmacological dry powder |
US6006747A (en) * | 1997-03-20 | 1999-12-28 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US6237590B1 (en) * | 1997-09-18 | 2001-05-29 | Delsys Pharmaceutical Corporation | Dry powder delivery system apparatus |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
NZ504021A (en) * | 1997-10-17 | 2003-04-29 | Systemic Pulmonary Delivery Lt | Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication |
AU5860098A (en) * | 1997-12-23 | 1999-07-19 | Euro-Celtique S.A. | Particle separator for an inhaler |
NL1008031C2 (en) * | 1998-01-15 | 1999-07-21 | Pharmachemie Bv | Device for inhaling medicament. |
AU749087B2 (en) * | 1998-03-04 | 2002-06-20 | Delsys Pharmaceutical Corporation | Medicament dry powder inhaler dispensing device |
GEP20043260B (en) * | 1998-03-16 | 2004-06-25 | Nectar Therapeutics | Aerosolized Active Agent Delivery and Device for Realization Thereof |
SE9801114D0 (en) * | 1998-03-30 | 1998-03-30 | Astra Ab | Inhalation device |
DE19831525A1 (en) * | 1998-07-14 | 2000-01-20 | Pfeiffer Erich Gmbh & Co Kg | Media Donor |
UA73924C2 (en) * | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
GB9902493D0 (en) * | 1999-02-05 | 1999-03-24 | Glaxo Group Ltd | Inhalation device |
US6752148B1 (en) | 1999-02-10 | 2004-06-22 | Delsys Pharmaceutical Company | Medicament dry powder inhaler dispensing device |
GB9905538D0 (en) | 1999-03-10 | 1999-05-05 | Glaxo Group Ltd | A device |
PL352615A1 (en) * | 1999-06-05 | 2003-08-25 | Innovata Biomed Ltd | Delivery system |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US6606992B1 (en) * | 1999-06-30 | 2003-08-19 | Nektar Therapeutics | Systems and methods for aerosolizing pharmaceutical formulations |
GB9920839D0 (en) | 1999-09-04 | 1999-11-10 | Innovata Biomed Ltd | Inhaler |
DE10027631B4 (en) * | 1999-10-06 | 2007-11-29 | Raul Goldemann | Breath-controlled dry powder inhaler and method for uniformly distributing the dry powder in air |
AU774573B2 (en) * | 1999-10-06 | 2004-07-01 | Eckardt, Angela | Breathing-controlled inhalation device for dry powder and method for the even distribution of said dry powder in the air |
GB9924415D0 (en) * | 1999-10-16 | 1999-12-15 | Glaxo Group Ltd | Medicament pack |
SE517806C2 (en) * | 1999-11-11 | 2002-07-16 | Microdrug Ag | Dosing device for inhaler |
US20010035184A1 (en) * | 1999-12-17 | 2001-11-01 | Carlos Schuler | Systems and methods for treating packaged powders |
US7069929B2 (en) * | 2000-02-01 | 2006-07-04 | Quadrant Technologies Limited | Dry powder inhaler |
DE60025889T2 (en) * | 2000-04-07 | 2006-08-03 | Andi-Ventis Ltd. | Mouthpiece for a device for inhaling particles |
JP4741159B2 (en) * | 2000-04-07 | 2011-08-03 | アンディベンティス リミテッド | Mouthpiece for granule inhaler |
WO2001078735A1 (en) * | 2000-04-13 | 2001-10-25 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
CA2410004A1 (en) | 2000-05-23 | 2001-11-29 | Glaxo Group Limited | Aerosol container for formulations of salmeterol xinafoate |
GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
PE20020067A1 (en) * | 2000-06-23 | 2002-02-05 | Norton Healthcare Ltd | DEAGGLOMERATOR FOR BREATH-ACTUATED DRY POWDER INHALER |
TWI224515B (en) * | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | Pre-metered dose magazine for breath-actuated dry powder inhaler |
GB0015801D0 (en) * | 2000-06-28 | 2000-08-16 | Innovata Biomed Ltd | Cover |
EP1172122A1 (en) * | 2000-07-14 | 2002-01-16 | The Technology Partnership Public Limited Company | Dry powder inhaler |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
AU2001283546A1 (en) | 2000-08-14 | 2002-02-25 | Advanced Inhalation Research, Inc. | Inhalation device and method |
WO2002013886A2 (en) * | 2000-08-15 | 2002-02-21 | University Of Kentucky Research Foundation | Programmable multi-dose intranasal drug delivery device |
SE517227C2 (en) * | 2000-09-25 | 2002-05-14 | Microdrug Ag | Dry powder inhaler with foil cutter |
FI20002363A0 (en) * | 2000-10-27 | 2000-10-27 | Orion Yhtymae Oyj | powder inhaler |
GB0026647D0 (en) | 2000-10-31 | 2000-12-13 | Glaxo Group Ltd | Medicament dispenser |
US7077130B2 (en) * | 2000-12-22 | 2006-07-18 | Chrysalis Technologies Incorporated | Disposable inhaler system |
WO2002053216A2 (en) * | 2001-01-08 | 2002-07-11 | Cipla Limited | An improved device for metered administration of medicament by inhalation |
US6443152B1 (en) * | 2001-01-12 | 2002-09-03 | Becton Dickinson And Company | Medicament respiratory delivery device |
US6644309B2 (en) * | 2001-01-12 | 2003-11-11 | Becton, Dickinson And Company | Medicament respiratory delivery device and method |
US6722364B2 (en) * | 2001-01-12 | 2004-04-20 | Becton, Dickinson And Company | Medicament inhalation delivery devices and methods for using the same |
WO2002062317A2 (en) * | 2001-02-06 | 2002-08-15 | Innovata Biomed Limited | Bimodal dry powder formulation for inhalation |
US6766799B2 (en) * | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
FI20011317A0 (en) * | 2001-06-20 | 2001-06-20 | Orion Corp | The powder inhaler |
US6871647B2 (en) * | 2001-09-19 | 2005-03-29 | Advent Pharmaceuticals Pty Ltd | Inhaler |
US7931022B2 (en) * | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
EP2308888B1 (en) | 2001-11-14 | 2017-03-01 | Janssen Biotech, Inc. | Anti-IL-6 antibodies, compositions, methods and uses |
GB0128148D0 (en) | 2001-11-23 | 2002-01-16 | Innovata Biomed Ltd | Assembly |
JP2005514393A (en) | 2001-12-19 | 2005-05-19 | ネクター セラピューティクス | Supplying aminoglycosides to the lung |
EP1487273B1 (en) | 2002-02-13 | 2009-01-21 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
US7185651B2 (en) * | 2002-06-18 | 2007-03-06 | Nektar Therapeutics | Flow regulator for aerosol drug delivery and methods |
WO2004002417A2 (en) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
EP1452198A4 (en) | 2002-10-11 | 2006-11-02 | Otsuka Pharma Co Ltd | Powder inhalation device |
AU2008201239B2 (en) * | 2002-10-11 | 2010-02-18 | Otsuka Pharmaceutical Co., Ltd. | Powder inhalation |
US6941947B2 (en) * | 2002-12-18 | 2005-09-13 | Quadrant Technologies Limited | Unit dose dry powder inhaler |
UA89481C2 (en) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
US20070277820A1 (en) * | 2003-10-27 | 2007-12-06 | Timothy Crowder | Blister packages and associated methods of fabricating dry powder drug containment systems |
WO2005040163A1 (en) | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd | Heterocyclic compounds that block the effects of advanced glycation end products (age) |
ITMO20040060A1 (en) * | 2004-03-18 | 2004-06-18 | Roberto Oliva | INHALER FOR POWDER PREPARATIONS |
MXPA06011425A (en) | 2004-03-31 | 2007-03-12 | Johnson & Johnson | Human glp-1 mimetibodies, compositions, methods and uses. |
BRPI0509348A (en) * | 2004-04-21 | 2007-09-11 | Innovata Biomed Ltd | inhaler |
GB0409197D0 (en) | 2004-04-24 | 2004-05-26 | Innovata Biomed Ltd | Device |
JP5078014B2 (en) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | Catalytic reaction of diketopiperazine synthesis. |
HUE026797T2 (en) | 2004-08-23 | 2016-07-28 | Mannkind Corp | Diketopiperazine salts for drug delivery |
US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
CA2616997C (en) * | 2004-09-13 | 2014-12-23 | Oriel Therapeutics, Inc. | Dry powder inhalers that inhibit agglomeration, related devices and methods |
JP2006130143A (en) * | 2004-11-08 | 2006-05-25 | Hitachi Ltd | Inhalation administration device and medicine cartridge |
GB0427858D0 (en) | 2004-12-20 | 2005-01-19 | Glaxo Group Ltd | Manifold for use in medicament dispenser |
GB0427853D0 (en) * | 2004-12-20 | 2005-01-19 | Glaxo Group Ltd | Manifold for use in medicament dispenser |
GB0427856D0 (en) * | 2004-12-20 | 2005-01-19 | Glaxo Group Ltd | Maniflod for use in medicament dispenser |
PE20061324A1 (en) | 2005-04-29 | 2007-01-15 | Centocor Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
HUE042561T2 (en) | 2005-06-30 | 2019-07-29 | Janssen Biotech Inc | Anti-IL-23 antibodies, compositions, methods and uses |
US8763605B2 (en) | 2005-07-20 | 2014-07-01 | Manta Devices, Llc | Inhalation device |
KR20120060245A (en) | 2005-09-14 | 2012-06-11 | 맨카인드 코포레이션 | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
DE102005057685A1 (en) * | 2005-12-01 | 2007-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhaler and storage for a dry drug formulation and methods and use thereof |
AR058289A1 (en) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | COLLECTOR TO BE USED IN MEDICINAL DISPENSER |
AR058290A1 (en) * | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | MEDICINAL DISPENSER |
DK3219328T3 (en) | 2005-12-29 | 2020-07-13 | Janssen Biotech Inc | HUMANE ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND USES |
EP2497484A3 (en) | 2006-02-22 | 2012-11-07 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
CA2644679C (en) * | 2006-03-03 | 2013-12-03 | Stc.Unm | Dry powder inhaler with aeroelastic dispersion mechanism |
JP2010500360A (en) | 2006-08-10 | 2010-01-07 | アルボア コーポレーション | Local therapy of lower respiratory inflammatory diseases with inflammatory cytokine inhibitors |
DE102006047667B3 (en) * | 2006-09-28 | 2008-04-24 | Ing. Erich Pfeiffer Gmbh | inhalator |
US9155849B2 (en) | 2006-10-19 | 2015-10-13 | G Greg Haroutunian | Flow modification device |
US8371291B2 (en) * | 2006-10-19 | 2013-02-12 | G. Greg Haroutunian | Flow modification device |
TW200843794A (en) | 2006-12-21 | 2008-11-16 | Centocor Inc | Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles |
US8141551B2 (en) * | 2007-02-16 | 2012-03-27 | Destal Industries, Inc. | Mouthpiece and flow rate controller for intrapulmonary delivery devices |
EP2150301B1 (en) * | 2007-06-01 | 2016-08-24 | Boehringer Ingelheim International GmbH | Dispensing device |
WO2008156586A2 (en) * | 2007-06-12 | 2008-12-24 | Alkermes, Inc. | Inhalation device for powdered substances |
RU2480248C2 (en) * | 2007-06-15 | 2013-04-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Inhaler |
EP2534957B1 (en) | 2007-12-14 | 2015-05-27 | AeroDesigns, Inc | Delivering aerosolizable products |
JP2011507593A (en) * | 2007-12-20 | 2011-03-10 | アストラゼネカ・アクチエボラーグ | Apparatus and method for deagglomerating and disassembling powder 854 |
EP2082762A1 (en) * | 2008-01-24 | 2009-07-29 | Boehringer Ingelheim International Gmbh | Inhaler |
EP2082764A1 (en) | 2008-01-24 | 2009-07-29 | Boehringer Ingelheim International GmbH | Inhaler |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
EP3281663B8 (en) | 2008-06-13 | 2022-09-21 | MannKind Corporation | Breath powered dry powder inhaler for drug delivery |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
WO2010008523A1 (en) | 2008-07-13 | 2010-01-21 | Map Pharmaceuticals, Inc. | Methods and apparatus for delivering aerosolized medication |
TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
KR20160116056A (en) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | Anti-il-12/il-23 antibodies |
BRPI0920658A2 (en) * | 2008-10-08 | 2016-01-12 | Astrazeneca Ab | inhalation device and method of dispensing medication |
GB0818476D0 (en) * | 2008-10-09 | 2008-11-12 | Vectura Delivery Device Ltd | Inhaler |
AU2009308935B2 (en) | 2008-10-31 | 2015-02-26 | Janssen Biotech, Inc. | Fibronectin type III domain based scaffold compositions, methods and uses |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
USD628288S1 (en) | 2009-01-22 | 2010-11-30 | Resmed Limited | Cuff for air delivery tube |
EP2396011B1 (en) | 2009-02-12 | 2016-04-13 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
PT2411521E (en) | 2009-03-25 | 2015-04-21 | Univ Texas | Compositions for stimulation of mammalian innate immune resistance to pathogens |
CN102458543B (en) | 2009-05-18 | 2015-02-04 | 3M创新有限公司 | Dry powder inhalers |
WO2010144789A2 (en) | 2009-06-12 | 2010-12-16 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
CN102711883B (en) | 2009-07-01 | 2015-04-08 | 阿斯利康(瑞典)有限公司 | Dispenser and method for entraining powder in an airflow |
IT1395945B1 (en) * | 2009-09-30 | 2012-11-02 | Oliva | INHALER PERFECTED FOR POWDER PREPARATIONS |
CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
EP2498848A2 (en) | 2009-11-12 | 2012-09-19 | Stc.Unm | Dry powder inhaler with flutter dispersion member |
JP5841072B2 (en) | 2010-02-10 | 2016-01-06 | イミュノジェン・インコーポレーテッド | CD20 antibody and use thereof |
WO2011116293A2 (en) * | 2010-03-19 | 2011-09-22 | Manta Devices, Llc | Delivery device and related methods |
USD635246S1 (en) * | 2010-03-26 | 2011-03-29 | Oriel Therapeutics, Inc. | Dose disk for dry powder inhalers |
EP2582722A4 (en) | 2010-06-19 | 2013-12-18 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
AU2011271097B2 (en) | 2010-06-21 | 2014-11-27 | Mannkind Corporation | Dry powder drug delivery system and methods |
RU2013104024A (en) * | 2010-07-21 | 2014-08-27 | Астразенека Аб | INHALER |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
DE102010048316B4 (en) * | 2010-10-14 | 2016-02-11 | Primed Halberstadt Medizintechnik Gmbh | Ventilation device with a holder for speaking valves and / or heat-moisture exchanger without cannula attachment |
USD666097S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
USD666492S1 (en) | 2010-11-01 | 2012-09-04 | Colgate-Palmolive Company | Cap for a container |
USD666096S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
USD666099S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
USD666493S1 (en) | 2010-11-01 | 2012-09-04 | Colgate-Palmolive Company | Cap for a container |
USD666098S1 (en) | 2010-11-01 | 2012-08-28 | Colgate-Palmolive Company | Cap for a container |
JP6050758B2 (en) | 2010-12-07 | 2016-12-21 | レスピラ セラピューティクス インコーポレイテッドRespira Therapeutics,Inc. | Dry powder inhaler and method of operating the same |
JOP20120023B1 (en) | 2011-02-04 | 2022-03-14 | Novartis Ag | Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases |
EP2688619B1 (en) * | 2011-03-21 | 2019-12-11 | Simplified Solutions Sweden AB | Inhalator for substances in powder form |
CN105667994B (en) | 2011-04-01 | 2018-04-06 | 曼金德公司 | Blister package for pharmaceutical kit |
WO2014067986A1 (en) | 2012-10-31 | 2014-05-08 | Galecto Biotech Ab | Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
WO2012175735A1 (en) | 2011-06-23 | 2012-12-27 | Vib Vzw | A20 inhibitors for the treatment of respiratory viral infections |
FR2979058B1 (en) * | 2011-08-19 | 2013-08-30 | Valois Sas | INHALATION DEVICE FOR POWDER. |
KR20140095483A (en) | 2011-10-24 | 2014-08-01 | 맨카인드 코포레이션 | Methods and compositions for treating pain |
US10463815B2 (en) | 2012-02-21 | 2019-11-05 | Respira Therapeutics, Inc. | Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents |
US10525216B2 (en) | 2012-02-21 | 2020-01-07 | Respira Therapeutics, Inc. | Powder dispersion methods and devices |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
US10105500B2 (en) * | 2012-05-09 | 2018-10-23 | Virginia Commonwealth University | Dry powder inhaler (DPI) designs for producing aerosols with high fine particle fractions |
DK2872205T3 (en) | 2012-07-12 | 2017-02-27 | Mannkind Corp | DRY POWDER FORMAL ADMINISTRATION SYSTEM |
US9248247B2 (en) * | 2012-07-26 | 2016-02-02 | Nathaniel Gerald Portney | Capsular medication delivery and inhalation device |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
AU2013365742B2 (en) | 2012-12-19 | 2016-11-24 | Novartis Ag | Autotaxin inhibitors |
TWI718086B (en) | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon |
US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
AU2014229361B2 (en) | 2013-03-14 | 2016-08-04 | Novartis Ag | Deamorphization of spray-dried formulations via spray-blending |
KR102499439B1 (en) | 2013-03-15 | 2023-02-13 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
CA2903576C (en) | 2013-03-15 | 2021-06-08 | Nai-Kong V. Cheung | High affinity anti-gd2 antibodies |
CN105209097B (en) | 2013-05-17 | 2020-03-31 | 皇家飞利浦有限公司 | Substance delivery module |
ES2742077T3 (en) | 2013-07-18 | 2020-02-13 | Novartis Ag | Autotaxin inhibitors comprising a cyclic benzyl amide heteroaromatic ring core |
EP3022201A1 (en) | 2013-07-18 | 2016-05-25 | Novartis AG | Autotaxin inhibitors |
WO2015010092A1 (en) | 2013-07-18 | 2015-01-22 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
DE102014005646B4 (en) * | 2014-01-30 | 2016-05-12 | Klaus-Dieter Beller | Powder inhaler and powder inhalation kit |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
WO2015162558A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Autotaxin inhibitors |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
CN107667120B (en) | 2015-03-17 | 2022-03-08 | 纪念斯隆-凯特林癌症中心 | anti-MUC 16 antibodies and uses thereof |
US10765821B2 (en) * | 2015-03-19 | 2020-09-08 | Altria Client Services Llc | Vaporizer for vaporizing a constituent of a plant material |
US10179215B2 (en) | 2015-03-19 | 2019-01-15 | Altria Client Services Llc | Vaporizer for vaporizing a constituent of a plant material |
CA2996635A1 (en) | 2015-09-09 | 2017-03-16 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
US10000561B2 (en) | 2015-09-09 | 2018-06-19 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules |
ES2925864T3 (en) | 2015-12-18 | 2022-10-20 | Galecto Biotech Ab | Polymorphous forms and process |
CA3021217A1 (en) * | 2016-04-18 | 2017-10-26 | Inspiring Pty Ltd | Spacer device for an inhaler |
WO2018014039A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors (cars) specific for muc1 and methods for their use |
BR112019000683A2 (en) | 2016-07-15 | 2019-04-24 | Poseida Therapeutics Inc | chimeric antigen receptors and methods for use |
CN106075677B (en) * | 2016-08-08 | 2022-06-10 | 中山市美捷时包装制品有限公司 | Actuating mechanism of dry powder inhalation device |
AU2017356673B2 (en) | 2016-11-09 | 2023-11-09 | Pulmotect, Inc. | Methods and compositions for adaptive immune modulation |
USD828653S1 (en) | 2016-12-14 | 2018-09-11 | Brandon Penland | Treatment applicator |
US10569069B2 (en) | 2016-12-14 | 2020-02-25 | Combat Comb, Llc | Applicator for treatments applied to animal skin |
EP3554503B1 (en) | 2016-12-16 | 2023-10-04 | The Board of Regents of The University of Texas System | Inhibitors of bromodomain-containing protein 4 (brd4) |
EP3574012A1 (en) | 2017-01-27 | 2019-12-04 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
JP2020506916A (en) | 2017-01-30 | 2020-03-05 | ヤンセン バイオテツク,インコーポレーテツド | Anti-TNF antibodies, compositions and methods for the treatment of active psoriatic arthritis |
KR20190115042A (en) | 2017-02-07 | 2019-10-10 | 얀센 바이오테크 인코포레이티드 | Anti-TNF Antibodies, Compositions, and Methods for the Treatment of Active Ankylosing Spondylitis |
BR112019019107A2 (en) * | 2017-03-15 | 2020-04-22 | Csp Technologies Inc | inhaler and methods of using and producing it |
KR101992171B1 (en) * | 2017-06-27 | 2019-06-25 | 한국유나이티드제약 주식회사 | Inhaler for dry powder |
US20210139557A1 (en) | 2017-12-20 | 2021-05-13 | Poseida Therapeutics, Inc. | Vcar compositions and methods for use |
JP2021523138A (en) | 2018-05-11 | 2021-09-02 | ヤンセン バイオテツク,インコーポレーテツド | How to treat depression with IL-23 antibody |
US11389433B2 (en) | 2018-06-18 | 2022-07-19 | Board Of Regents, The University Of Texas System | BRD4 inhibitor treatment of IgE-mediated diseases |
KR20210116540A (en) | 2019-01-15 | 2021-09-27 | 얀센 바이오테크 인코포레이티드 | Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
CN113330031A (en) | 2019-01-23 | 2021-08-31 | 詹森生物科技公司 | anti-TNF antibody compositions for use in methods of treating psoriatic arthritis |
US20220153830A1 (en) | 2019-03-14 | 2022-05-19 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
EP3938391A1 (en) | 2019-03-14 | 2022-01-19 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
CA3133388A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
EP3972690A4 (en) | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
AU2020288404A1 (en) | 2019-06-03 | 2022-02-03 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis |
EP3976648A1 (en) | 2019-06-03 | 2022-04-06 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
US11458262B2 (en) | 2019-06-25 | 2022-10-04 | Altria Client Services Llc | Capsules, heat-not-burn (HNB) aerosol-generating devices, and methods of generating an aerosol |
USD916361S1 (en) | 2019-06-25 | 2021-04-13 | Altria Client Services Llc | Aerosol-generating capsule |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
CN115996747A (en) | 2020-04-14 | 2023-04-21 | 波赛达治疗公司 | Compositions and methods for treating cancer |
WO2021214588A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating coronavirus infections |
WO2021214587A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating viral infections |
US20230312684A1 (en) | 2020-07-31 | 2023-10-05 | Pinetree Therapeutics, Inc. | Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections |
US11789476B2 (en) | 2021-01-18 | 2023-10-17 | Altria Client Services Llc | Heat-not-burn (HNB) aerosol-generating devices including intra-draw heater control, and methods of controlling a heater |
US11910826B2 (en) | 2021-01-18 | 2024-02-27 | Altria Client Services Llc | Heat-not-burn (HNB) aerosol-generating devices and capsules |
WO2023279115A1 (en) | 2021-07-02 | 2023-01-05 | Henry Ford Health System | Compositions comprising endosidin 2 for reducing sars-cov-2 infection |
AU2022306144A1 (en) | 2021-07-09 | 2024-02-22 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
WO2023281463A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3288277A (en) * | 1965-09-22 | 1966-11-29 | Richardson Merrell Inc | Dispensing container |
US3437236A (en) * | 1967-09-26 | 1969-04-08 | Ortho Pharma Corp | Tablet dispensing device |
SE8603252L (en) * | 1985-07-30 | 1987-01-31 | Glaxo Group Ltd | DEVICE FOR SUPPLYING MEDICINE TO PATIENTS |
SE453566B (en) | 1986-03-07 | 1988-02-15 | Draco Ab | POWDER INHALATOR DEVICE |
GB8614805D0 (en) | 1986-06-18 | 1986-07-23 | British American Tobacco Co | Aerosol device |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
GB9021433D0 (en) * | 1990-10-02 | 1990-11-14 | Atomic Energy Authority Uk | Power inhaler |
US5492112A (en) * | 1991-05-20 | 1996-02-20 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
GB2264237A (en) * | 1992-02-05 | 1993-08-25 | Robert Edward Newell | An inhaler |
EP0558879B1 (en) * | 1992-03-04 | 1997-05-14 | Astra Aktiebolag | Disposable inhaler |
DE4208880A1 (en) * | 1992-03-19 | 1993-09-23 | Boehringer Ingelheim Kg | SEPARATOR FOR POWDER INHALATORS |
US5896855A (en) * | 1992-12-24 | 1999-04-27 | Rhone-Poulenc Rorer Limited | Multi dose inhaler apparatus |
US5388572A (en) * | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
US5622166A (en) * | 1995-04-24 | 1997-04-22 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
-
1996
- 1996-12-19 EA EA199800556A patent/EA001016B1/en not_active IP Right Cessation
- 1996-12-19 EA EA199900400A patent/EA001237B1/en not_active IP Right Cessation
- 1996-12-19 DE DE69618624T patent/DE69618624T2/en not_active Expired - Fee Related
- 1996-12-19 DE DE69617754T patent/DE69617754T2/en not_active Expired - Fee Related
- 1996-12-19 AU AU11633/97A patent/AU725348B2/en not_active Ceased
- 1996-12-19 AT AT96942494T patent/ATE209053T1/en not_active IP Right Cessation
- 1996-12-19 IL IL12518396A patent/IL125183A0/en unknown
- 1996-12-19 PL PL96327616A patent/PL327616A1/en unknown
- 1996-12-19 KR KR1019980705145A patent/KR19990077014A/en not_active Application Discontinuation
- 1996-12-19 CN CN96180172A patent/CN1213974A/en active Pending
- 1996-12-19 CA CA002241880A patent/CA2241880A1/en not_active Abandoned
- 1996-12-19 BR BR9612410A patent/BR9612410A/en not_active Application Discontinuation
- 1996-12-19 US US09/101,102 patent/US6065472A/en not_active Expired - Fee Related
- 1996-12-19 JP JP9524939A patent/JP2000503565A/en active Pending
- 1996-12-19 ES ES99201271T patent/ES2167987T3/en not_active Expired - Lifetime
- 1996-12-19 EP EP99201271A patent/EP0938907B1/en not_active Expired - Lifetime
- 1996-12-19 AT AT99201271T patent/ATE209939T1/en not_active IP Right Cessation
- 1996-12-19 ES ES96942494T patent/ES2166473T3/en not_active Expired - Lifetime
- 1996-12-19 EP EP96942494A patent/EP0883414B1/en not_active Expired - Lifetime
- 1996-12-19 AP APAP/P/1998/001285A patent/AP9801285A0/en unknown
- 1996-12-19 CZ CZ982125A patent/CZ212598A3/en unknown
- 1996-12-19 WO PCT/GB1996/003141 patent/WO1997025086A2/en not_active Application Discontinuation
- 1996-12-19 NZ NZ324374A patent/NZ324374A/en unknown
- 1996-12-19 TR TR1998/01265T patent/TR199801265T2/en unknown
-
1998
- 1998-06-29 IS IS4787A patent/IS4787A/en unknown
- 1998-07-02 NO NO983069A patent/NO983069L/en not_active Application Discontinuation
- 1998-07-02 MX MX9805409A patent/MX9805409A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6065472A (en) | Multidose powder inhalation device | |
CA2283199C (en) | Inhalation device | |
JP5297719B2 (en) | Deagglomeration device | |
FI103952B (en) | Device for administering powdered medical substances | |
CA2369726C (en) | Powder inhaler for combined medicament | |
EP0481666A1 (en) | Powder inhaler device | |
US20060021616A1 (en) | Inhaler | |
PL172758B1 (en) | Dry powder inhaler | |
HU217896B (en) | Inhalation device | |
KR20060106627A (en) | Pre-metered dose magazine for dry powder inhaler | |
KR20140064778A (en) | Improvements relating to delivery devices | |
KR101995603B1 (en) | Improvements relating to delivery devices | |
AU740228B2 (en) | Inhalation device | |
AU3429702A (en) | Inhalation device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |